GOTHENBURG, SWEDEN – IRLAB Therapeutics, a company discovering and developing novel treatments for Parkinson’s disease, today announced that the US FDA has granted an end-of-Phase 2 meeting for the mesdopetam program on February 20, 2024. “The end-of-Phase 2 meeting is an important milestone for the mesdopetam program. The further development...
treatment News
BOSTON, Mass. – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure...
Cleveland — iRxReminder LLC, a health technology company, is pleased to announce that it has received a NIH Award to validate its patented technology and approach to improve patient outcomes in managing Tardive Dyskinesia (TD), a movement disorder characterized by uncontrollable, abnormal, and repetitive movements that may affect as many...
MILAN – The Italfarmaco Group announced a publication in the Blood Cancer Journal outlining the first interim analysis results from follow-up of a mean of four years in 51 patients with polycythemia vera (PV), a type of hematological malignancy belonging to BCR-ABL1-negative chronic myeloproliferative neoplasms (MPNs). The results show a long-term benefit in PV patients...
MILAN – Italfarmaco Group announced today topline data from its proof-of-concept Phase 2 trial with Givinostat, the company’s proprietary histone deacetylase (HDAC) inhibitor, in 51 adult males with Becker Muscular Dystrophy (BMD). The study was designed to evaluate the effect of Givinostat in BMD, building on the experience developed in Duchenne Muscular...
MILAN, Italy – Italfarmaco S.p.A. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to givinostat for the treatment of patients with polycythemia vera (PV), a rare haematologic cancer, for which treatment options are limited. “The FDA decision to grant givinostat Fast Track designation underscores the...
MILAN, Italy – Italfarmaco S.p.A. announced today that additional data on givinostat for the treatment of Duchenne muscular dystrophy (DMD) are being presented at the 30th annual International Congress of the World Muscle Society (WMS) held October 7-11 in Vienna, Austria. Poster presentations highlight the long-term safety of givinostat in patients with DMD,...
MILAN, Italy — Italfarmaco S.p.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Duvyzat™ (givinostat), a novel histone deacetylase (HDAC) inhibitor, for the treatment of patients 6 years or older with Duchenne muscular dystrophy (DMD), a rare X-linked progressive and life-limiting neuromuscular condition with symptoms from...
ORLANDO, Florida — Until Susan Caldwell of Waxahachie, Texas, learned in 2016 that her 8-year-old son Ryan Michael had Duchenne muscular dystrophy (DMD), she had never heard of the disease—and only vaguely knew of muscular dystrophy, thanks to the Jerry Lewis Telethon. “It was devastating,” she recalled. “I had met...
HOUSTON – Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has confirmed the safety of Tegavivint, a novel, potent and selective nuclear beta-catenin inhibitor, after completing enrollment and dosing the final patient in a multicenter Phase 1/2a dose expansion clinical study...